# Efficacy and Safety of Desmopressin (Nocturin®) 0.1 mg Tablets in Treatment of Nocturia in Participants With Benign Prostate Syndrome (BPS)

> **NCT00902265** · — · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 138 (actual)

## Conditions studied

- Nocturia Associated With Nocturnal Polyuria

## Interventions

- **DRUG:** desmopressin

## Key facts

- **NCT ID:** NCT00902265
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 138 (ACTUAL)
- **Last updated:** 2011-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00902265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00902265, "Efficacy and Safety of Desmopressin (Nocturin®) 0.1 mg Tablets in Treatment of Nocturia in Participants With Benign Prostate Syndrome (BPS)". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00902265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*